Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cagrilintide pharmacokinetics in hepatic impairment and bioavailability in healthy volunteers
NCT05564104Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2023
- Primary completion
- Sep 2024
- Modality
- Peptides, Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of cagrilintide in obesity (6 arms), sponsored by Novo Nordisk. Primary endpoint: Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity at 840 hours. Started Apr 2023; status: completed.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05564104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564104.